Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes.

Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, Liberopoulos EN, Elisaf M.

Atherosclerosis. 2010 Oct;212(2):607-13. doi: 10.1016/j.atherosclerosis.2010.06.006. Epub 2010 Jun 11.

PMID:
20594556
2.

Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein.

Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS, Tselepis AD.

Lipids. 2011 Oct;46(10):953-60. doi: 10.1007/s11745-011-3580-y. Epub 2011 Jun 19.

PMID:
21688175
3.

Visceral leishmaniasis is associated with marked changes in serum lipid profile.

Liberopoulos EN, Apostolou F, Gazi IF, Kostara C, Bairaktari ET, Tselepis AD, Elisaf M.

Eur J Clin Invest. 2014 Aug;44(8):719-27. doi: 10.1111/eci.12288.

PMID:
24920396
4.

Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.

Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M, Liberopoulos EN.

J Lipid Res. 2009 Dec;50(12):2532-9. doi: 10.1194/jlr.P900063-JLR200. Epub 2009 Jun 17.

6.
7.

Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles.

Bekaert ED, Alaupovic P, Knight-Gibson CS, Franceschini G, Sirtori CR.

J Lipid Res. 1993 Jan;34(1):111-23.

8.

Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.

Dullaart RP, Constantinides A, Perton FG, van Leeuwen JJ, van Pelt JL, de Vries R, van Tol A.

J Clin Endocrinol Metab. 2011 Apr;96(4):1077-84. doi: 10.1210/jc.2010-2139. Epub 2011 Jan 20.

PMID:
21252249
9.

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.

Saumoy M, Sánchez-Quesada JL, Martínez E, Llibre JM, Ribera E, Knobel H, Gatell JM, Clotet B, Curran A, Curto J, Masó M, Ordoñez-Llanos J, Podzamczer D.

Atherosclerosis. 2012 Nov;225(1):200-7. doi: 10.1016/j.atherosclerosis.2012.08.010. Epub 2012 Sep 6.

PMID:
23017355
10.

Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.

Gugliucci A.

Clin Chim Acta. 2014 Feb 15;429:38-45. doi: 10.1016/j.cca.2013.11.021. Epub 2013 Nov 23.

PMID:
24280342
11.

Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.

Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.

Metabolism. 2000 Feb;49(2):167-77.

PMID:
10690940
12.

LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.

Ambrosch A, Mühlen I, Kopf D, Augustin W, Dierkes J, König W, Luley C, Lehnert H.

Diabetes Care. 1998 Dec;21(12):2077-84.

PMID:
9839097
14.

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.

Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2236-43. Epub 2007 Jul 26.

15.

Small Dense Low Density Lipoprotein Cholesterol, Paraoxonase 1 and Lipid Profile in Postmenopausal Women: Quality or Quantity?

Mogarekar MR, Kulkarni SK.

Arch Med Res. 2015 Oct;46(7):534-8. doi: 10.1016/j.arcmed.2015.08.007. Epub 2015 Sep 5.

PMID:
26348135
16.

Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.

Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS.

Arch Med Res. 2007 May;38(4):403-10.

PMID:
17416287
17.

Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.

Kappelle PJ, Gansevoort RT, Hillege HJ, Wolffenbuttel BH, Dullaart RP; PREVEND Study Group.

J Clin Lipidol. 2013 Jan-Feb;7(1):56-64. doi: 10.1016/j.jacl.2012.05.003. Epub 2012 May 22.

PMID:
23351584
19.

Evaluation of serum lipid abnormalities in chronic nephritis.

Hirano H, Yamada Y, Otani H, Kodama N, Mune M, Yukawa S.

Kidney Int Suppl. 1999 Jul;71:S147-9.

PMID:
10412761
20.

Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.

Rashid S, Sniderman A, Melone M, Brown PE, Otvos JD, Mente A, Schulze K, McQueen MJ, Anand SS, Yusuf S.

Eur J Prev Cardiol. 2015 Apr;22(4):468-77. doi: 10.1177/2047487314528461. Epub 2014 Mar 21.

PMID:
24659026

Supplemental Content

Support Center